Theoretical basis for interest in acetylprocainamide and clinical experiences with this new antiarrhythmic agent.
In conclusion, it was the differential responses of slow and rapid acetylators to procainamide therapy that gave the initial clues that acetylprocainamide might be a safer drug than procainamide. So far, the experience with acetylprocainamide has been encouraging.
D000120:Acecainide / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000107:Acetylation; D000818:Animals; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D007536:Isomerism; D007700:Kinetics; D011342:Procainamide / Q000031:analogs & derivatives* / Q000378:metabolism
D000120:Acecainide; D011342:Procainamide